UK multinational to sell new cancer medicines in Kenya
17 days ago, 17:02
UK-based drugmaker, Clinigen, has announced plans to introduce its three cancer drugs in the Kenyan market. In a statement, Clinigen Group Plc said it had granted Eisai Europe exclusive rights to seek licences from Kenyan authorities for the three brands, Halaven (eribulin), Fycompa (perampanel) and Lenvima (lenvatinib). Clinigen’s South Africa managing director Benjamin Miny said: “We are able to leverage our extensive distribution network in the region and local expertise to enable acces ...
Category: business news corporate economy opinion markets lifestyle